Chances are that you, or someone you know, has had lower back pain get in the way of daily life. For some people it is merely an inconvenience, but for many, it is debilitating. In the United States, over 70% of adults suffer from back pain at some time during their lives. Lower back pain is the second-most common reason for missed work, after the common cold. Lost productivity due to lower back pain is estimated to be over $30 billion dollars annually.
Out of the myriad causes of lower back pain, one of the most common is degeneration of the intervertebral disk. The intervertebral disk is like a shock absorber between bones in the spine. As people age, wear-and-tear on these disks leads to damage: essentially only children have intervertebral disks without any signs of deterioration. By middle age, lower back pain is sometimes bad enough that people resort to invasive surgeries.
Ward Shalash, a first-year PhD student studying bioengineering with Dr. Morgan Giers, is working to find a better way to treat deteriorated intervertebral disks. Currently, the primary method for treating severe back pain caused by a deteriorated intervertebral disk is to either replace the disk with an artificial disk, or to remove the disk and fuse the neighboring vertebra. Although these methods are effective in relieving pain, patients often need to have the procedure redone after ten years. In addition, particularly for the method where vertebra are fused, patients experience loss of flexibility. In 2003 a new method, cell replacement therapy, was demonstrated on a rabbit. This treatment involves collecting mesenchymal stem cells from a patient (generally from fat cells), and injecting them into the gel-like material in the center of the intervertebral disk. Ideally, this process allows the disk to be restored in place. While this treatment has been applied with some success to human patients, the procedure is not yet standardized or tested well enough for FDA approval in the US. In particular it isn’t yet clear how to determine the number of cells to inject for best results.
This is where Ward’s research comes in. “The goal is to develop a method so that doctors can know whether cell replacement therapy will work for patients or not,” said Ward. An intervertebral disk consists of three main parts: the nucleous puplosus, a jelly-like substance in the center; the anulus fibrosus, stiff, fibrous walls around the jelly center; and cartilage endplates above and below.
Cells require a supply of nutrients to survive; as there is no blood flow into the disk, cells inside rely on water seeping through the cartilage endplates. Dissolved in the water are nutrients such as glucose and oxygen which are vital for cell survival.
Ward uses a combination of MRI imaging and mathematical modeling to study the flow of water through the intervertebral disk. From this information, he hopes to find a method doctors can use to determine the number of stem cells to inject. Ward hopes that the ability to algorithmically predict the success of treatment this way would cut down the cost of clinical trials.
Ward first came to Oregon as an exchange student from Israel. After finishing an associate’s degree at Portland Community College, he came to Oregon State to study bioengineering. He has a dream of a world where people don’t have to worry about injuries. One of his concerns is making sure that progress in bioengineering is ethical. For example, says Ward, “How do you make sure that it’s accessible for all kinds of people?”
Along with his academic pursuits, Ward enjoys the outdoors, playing the oud, and volunteering. To hear more about Ward’s story and his science, tune in this Sunday at 7PM (PST). You can stream the show live online, or listen to the interview live on the air at 88.7 KBVR FM, Corvallis. If you miss the broadcast, you can also listen to the episode on our podcast soon after the broadcast.
Summary of stem cell treatment for back pain: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347696/
Discussion of current strategies for treatment of lower back pain: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651638/